IoM Committee To Hear CDER, PhRMA Perspectives On Drug Safety System
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Acting Director Galson will outline FDA's charge to the Institute of Medicine drug safety committee, while PhRMA Regulatory Affairs VP Goldhammer will discuss industry perspectives at the first meeting of the ad hoc committee June 8.
You may also be interested in...
FDA Drug Safety Review Will Consider Pros And Cons Of Separate Safety Agency
The agency is in discussions with the Institute of Medicine to initiate a study on the effectiveness of the drug safety system, particularly in the post-marketing phase. The IoM study is the centerpiece of an FDA drug safety initiative, announced Nov. 5, that packages together ongoing projects.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.